Sanjoy Bhattacharya, MD
Clinical Cardiac Electrophysiology · Phoenix, AZNPI 1710150693
Payments from drug & device makers
Across 408 payments — averaging $102.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$21K
- AbbVie$9K
- Medtronic$4K
- Boston Scientific$3K
- Novartis$787
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$682
- plus $4K from 33 others
What the payments were for
- Consulting fees$20,73450%
- Speaking & faculty fees$1,7004%
- Travel & lodging$3,9079%
- Food & beverage$15,31737%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 125 | $21,179 |
| AbbVie | 7 | $9,182 |
| Medtronic(2 entities) | 34 | $3,680 |
| Boston Scientific | 28 | $2,521 |
| Novartis | 43 | $787 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $682 |
| Biosense Webster, Inc. | 9 | $539 |
| Johnson & Johnson | 20 | $344 |
| Abiomed | 4 | $293 |
| AstraZeneca | 9 | $291 |
| Boehringer Ingelheim | 10 | $255 |
| Bardy Diagnostics, Inc. | 13 | $220 |
| Amgen | 11 | $204 |
| E.r. Squibb & Sons, L.L.C. | 12 | $186 |
| Impulse Dynamics (USA) Inc. | 3 | $143 |
| Merck | 9 | $137 |
| Amarin Pharma, Inc. | 5 | $91 |
| Chiesi USA, Inc. | 6 | $90 |
| Pfizer | 5 | $82 |
| Actelion Pharmaceuticals US, Inc. | 3 | $75 |
| Atricure, Inc. | 1 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Cleerly, Inc. | 1 | $64 |
| Kestra Medical Technology Services, Inc. | 2 | $55 |
| Edwards Lifesciences | 2 | $51 |
| ZOLL Respicardia, Inc. | 2 | $46 |
| Inspire Medical Systems, Inc. | 2 | $46 |
| Novo Nordisk | 2 | $45 |
| Philips North America LLC | 2 | $32 |
| Innovation Technologies Inc | 1 | $28 |
| Baxter Healthcare | 1 | $26 |
| Cvrx, Inc. | 1 | $25 |
| Itamar Medical Inc | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Elutia, Inc. | 1 | $16 |
| Cardiva Medical, Inc. | 1 | $16 |
| Preventice Services, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Allure Quadra RF CRT Pacemaker$5,395
- Assurity Pacemaker$2,583
- Quadra Assura CRT Defibrillator$2,368
- AVEIR$1,694
- Fortify Assura, Ellipse ICD$1,615
- Farapulse$1,005
- Quadra Allure MP RF CRT Pacemkr$665
- Carto 3$348
- CardioMEMS HF System$330
- GALLANT$328
- Optisure Defibrillation ICD Lead$319
- MitraClip$309
- CoreValve Evolut$306
- Micra$293
- Impella$253
- Mitra Clip system$245
- ENSITE$245
- OPTIMIZER$221
- Watchman$221
- Allure CRT Pacemaker$190
How this compares
$41,662 in reported general payments places this provider in the 40th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
See all clinical cardiac electrophysiology providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 444 | $559,491 |
| XareltoRivaroxaban | 72 | $101,307 |
| FarxigaDapagliflozin Propanediol | 72 | $78,027 |
| EntrestoSacubitril/Valsartan | 49 | $76,171 |
| JardianceEmpagliflozin | 44 | $69,077 |
| MultaqDronedarone Hcl | 31 | $59,359 |
| Repatha SureclickEvolocumab | 20 | $15,959 |
| Metoprolol Succinate | 337 | $7,587 |
| Atorvastatin Calcium | 379 | $3,705 |
| Carvedilol | 390 | $3,569 |
| Flecainide Acetate | 51 | $2,672 |
| Ezetimibe | 88 | $2,162 |
| Rosuvastatin Calcium | 121 | $2,139 |
| Bumetanide | 36 | $1,967 |
| Losartan Potassium | 246 | $1,945 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $559,491444 claims |
| Johnson & JohnsonXarelto | $344 | $101,30772 claims |
| AstraZenecaFarxiga | $291 | $78,02772 claims |
| NovartisEntresto | $787 | $76,17149 claims |
| Boehringer IngelheimJardiance | $255 | $69,07744 claims |
| Sanofi-aventis U.S. LLCMultaq | $72 | $59,35931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 80 clinical cardiac electrophysiology providers in Arizona.
Other clinical cardiac electrophysiology in Phoenix
- Vijendra SwarupPhoenix$5.1M
- Akash MakkarPhoenix$3.4M
- Marwan BahuPhoenix$1.7M
- Yoaav KrauthammerPhoenix$385K
- Jonathan WeissPhoenix$299K
- Paul HaasPhoenix$136K
- Michael ZawanehPhoenix$84K
- Praneeth KatrapatiPhoenix$76K
- Komandoor SrivathsanPhoenix$57K
- Mark SeifertPhoenix$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.